WHO signs MoU with International Generic and Biosimilar Medicines Association to promote access (October 2019)Full access to medicines is hampered by a variety of factors. Two important barriers are high prices and regulatory issues such as long lag times in bringing medicines to market. Read More
IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019) Read More
The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019) Read More
Op-ed: Trade agreement drug monopoly is obsolete given faster, better drug discoveryOctober 2, 2019. For decades, the brand-name drug industry has relentlessly promoted the message that any reduction in its government-protected monopolies would have detrimental effects on innovation. Members of Congress on both sides of the aisle have taken that message… Read More
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in late 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).